

---

**Kanagawa, Japan, October 25, 2019** - Chordia Therapeutics, oncology R&D company developing First-in-Class small-molecule assets, today announced that it is expanding its leadership team with the appointments of Daisuke Morishita, Ph.D. as its Chief Scientific Officer and Kunihiro Takeyama M.D., Ph.D. as its Chief Medical Officer. Dr. Morishita is one of co-founders of Chordia Therapeutics and serving as Senior Director of Discovery. Dr. Takeyama was ex head of Oncology Therapeutic Area Unit at Takeda Pharmaceuticals and most recently serving as Professor of Center for Research Administration and Innovation at Tokyo Medical University, Tokyo, Japan. Dr. Morishita will lead discovery and pre-clinical sciences and Dr. Takeyama will be responsible for all clinical development related activities.

“Daisuke and Kuni have wide range of experiences in drug discovery and development and their guidance on the pipeline is critical for their success. Their strategic inputs are important to achieve pre-clinical and clinical milestones.” said Hiroshi Miyake, Ph.D., president and Chief Executive Officer of Chordia Therapeutics. “Our lead asset CTX-712, a CLK inhibitor, is under First-in-Human Phase I clinical trial to explore its safety, pharmacokinetics and efficacy. Kuni’s leadership and network with oncology top KOLs in both Japan and US will accelerate clinical development of CTX-712. And Daisuke will play a critical role to deliver our second pipeline MALT1 CTX-177 to clinical stage in 2020.”

“Chordia is science driven oncology research and development company. Our discovery team has expertise in pharmacology, chemistry, computational science and bioinformatics allowing fast and effective candidate selection. With scientific advisors and collaborators, we intend to drive pipeline assets toward to clinical stage.” Dr. Morishita said

“I am really thrilled to join Chordia Therapeutics dedicated to oncology drug development. This is a significant and exciting time for Chordia’s all programs at different stages, especially for a company’s lead compound, CTX-712, a first-in class CLK inhibitor. I look forward to working with an enthusiastic team and delivering innovative drugs to change paradigms of cancer treatment.” Dr. Takeyama said.

### **About Chordia Therapeutics**

Chordia Therapeutics is an oncology drug discovery and development company focusing on advancing innovative assets to deliver transformative therapies to cancer patients. The company is backed by Japanese venture capital syndicates co-led by Kyoto iCAP and JAFCO.

For more information, visit [www.chorditherapeutics.com](http://www.chorditherapeutics.com).

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012 Japan

[info@chorditherapeutics.com](mailto:info@chorditherapeutics.com)



---

**Media Contact**

[info@chorditherapeutics.com](mailto:info@chorditherapeutics.com)